Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012Source: DataRank Database

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808 is a research paper published in Clinical Genitourinary Cancer (2023). On theSindex it has a DataRank of 0.261. It has been cited 4 times, with 4 citing works in its 1-hop citation network.

N/A

0.261DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access4 citations · 4 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01164228

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 0.66)OA: greenTopics (20)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 93%Citation Network 7%

Base Score Contribution

0.241

From this paper's citation signal

Citation Network Contribution

0.0193

From 1 citing papers with measurable signal

Learn more about DataRank methodology →

Top 4 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 4 citers.

Special populations in metastatic renal cell carcinoma
Current Opinion in Oncology20243 citations61 referencesContributes 0.023
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysis
Research Square20250 citations33 referencesContributes 0.000
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis
BMC Cancer20260 citations49 referencesContributes 0.000
Epithelial-mesenchymal transition and sunitinib resistance in renal cell carcinoma: mechanisms and therapeutic strategies
Frontiers in Pharmacology20260 citations156 referencesContributes 0.000

Authors (15)

Se Eun Kim ORCID,David F. McDermott ORCID,Janice P. Dutcher ORCID,Mäneka Puligandla,Judith Manola ORCID

Live enrichment

PubMed:37455214 PMC:PMC10543556 OpenAlex:https://openalex.org/W4382933719

National Institutes of Health

Grant: U10CA180794

National Institutes of Health

Grant: UG1CA189830

National Institutes of Health

Grant: UG1CA232760

National Institutes of Health

Grant: UG1CA233184

National Institutes of Health

Grant: UG1CA233196

National Institutes of Health

Grant: UG1CA233247

National Institutes of Health

Grant: UG1CA233320

National Cancer Institute

Grant: U10CA180820

NCI NIH HHS

Grant: U24 CA196172

ECOG-ACRIN Cancer Research Group

FWCI

0.66

Citation Percentile

0.7%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10543556/pdf/nihms-1919993.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1558767323001519?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1558767323001519?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10543556

Fields of Study

Renal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsSarcoidosis and Beryllium Toxicity Research

MeSH Terms

SunitinibGemcitabineAntineoplastic AgentsCarcinoma, Renal CellHumansKidney Neoplasms

Keywords

SunitinibMedicineRenal cell carcinomaGemcitabineOncologyInternal medicineRandomized controlled trialUrologyCancerRenal cellSarcomatoid

Sustainable Development Goals

SDG 0: No poverty

Related Papers (10)

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

N/A

1.9DataRank · unranked

ESMO Open(2024)

co-cited

10.1016/j.esmoop.2024.102994

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial

N/A

0.406DataRank · unranked

Nature Communications(2025)

co-cited

10.1038/s41467-024-55642-8

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents

N/A

0.241DataRank · unranked

Clinical Genitourinary Cancer(2022)

co-citedsame journal

10.1016/j.clgc.2022.04.010

Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer

British Journal of Cancer(2021)

co-cited

10.1038/s41416-021-01385-y

Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR

N/A

0.624DataRank · unranked

Oncogene(2021)

co-cited

10.1038/s41388-020-01616-1

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

N/A

2.7DataRank · unranked

Journal for ImmunoTherapy of Cancer(2022)

co-cited

10.1136/jitc-2022-005445

Metastasis

Cell(2023)

co-cited

10.1016/j.cell.2023.03.003

Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma

N/A

0.292DataRank · unranked

Current Opinion in Oncology(2023)

co-cited

10.1097/cco.0000000000000939

CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance

iScience(2024)

co-cited

10.1016/j.isci.2024.110224

LncRNA-SERB promotes vasculogenic mimicry (VM) formation and tumor metastasis in renal cell carcinoma

Journal of Biological Chemistry(2024)

co-cited

10.1016/j.jbc.2024.107297

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

FAIR Checklist

DataRank Breakdown

Top 4 citers driving the network score

Authors (15)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)

Related Papers (10)